Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 3 JAK inhibitors and their targets related in the article

From: JAK inhibitors: a new choice for diabetes mellitus?

Drug

Indications

Targets

Refs

Baricitinib

Rheumatoid Arthritis, COVID-19, Severe Alopecia Areata

JAK1 JAK2

[50,51,52,53]

Ruxolitinib

High-RiskMyelofibrosis, PolycythaemiaVera, Steroid-Refractory Acute Graft-Versus-Host Disease

JAK1 JAK2

[54,55,56]

AZD1480

None

JAK1 JAK2

None

Upadacitinib(ABT494)

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Atopic Dermatitis, Ulcerative Colitis, Crohn's Disease

JAK1

[18]

JANEX-1

None

JAK3

none

Deucravacitinib

Moderate to Severe Plaque Psoriasis

TYK2

[21, 42]

Tofacitinib

Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Polyarticular Juvenile Idiopathic Arthritis

JAK1 JAK3

[57,58,59,60,61,62]

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us